Key result
Alpha-fetoprotein, discovered by Yuri Semenovich Tatarinov in 1963, remains a prominent oncobiomarker for hepatocellular carcinoma, commemorated at a 50th-anniversary conference in Russia.
Commemorates the 50th anniversary of the discovery of alpha-fetoprotein as a tumor marker by Yuri Semenovich Tatarinov.
Alpha-fetoprotein represents the most prominent oncobiomarker, widely used in the diagnosis of hepatocellular carcinoma for monitoring of tumor progression, presence of metastasis, assessment of cancer prognosis and successful antitumor therapeutic measures. Yuri Semenovich Tatarinov is a Russian scientist who first published antigen specific for human hepatocellular carcinoma in 1963. To commemorate the 50th anniversary of the discovery of alpha-fetoprotein, 9th International Scientific-Practical Conference entitled "Achievements of fundamental science and translational medicine capabilities in solving actual problems of practical public health" was held from May 6-8th, 2013 in Astrakhan, Russia.The conference was held in memory of historical scientific work of Yuri Semenovich Tatarinov.
No takes yet. Share an insight, caveat, or question.
Никулина et al. (2015) conducted a review in Hepatocellular carcinoma. Alpha-fetoprotein was evaluated. Alpha-fetoprotein, discovered by Yuri Semenovich Tatarinov in 1963, remains a prominent oncobiomarker for hepatocellular carcinoma, commemorated at a 50th-anniversary conference in Russia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: